Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
single dose · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK1144814 | EXPERIMENTAL | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| placebo | PLACEBO_COMPARATOR | Subjects will receive either GSK1144814 or placebo at each treatment arm. |
| placebo arm | PLACEBO_COMPARATOR | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| GSK561679 arm | EXPERIMENTAL | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| lorazepam arm | ACTIVE_COMPARATOR | There are single dose treatment arms of GSK561679, lorazepam as well as placebo. |
| Name | Type | Description |
|---|---|---|
| single dose | DRUG | Subjects will receive a single dose of GSK1144814 or placebo. |
Inclusion Criteria: * Healthy male and female * Body weight 50 kg or higher and BMI within the range 19 - 29.9 kg/m2 * Willing to use appropriate contraception methods Exclusion Criteria: * Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody result * Any serious medical disorder or ...
GSK561679 is an investigational drug being studied for use in depressive disorder and anxiety disorders. It was evaluated in a Phase 1 clinical trial in healthy volunteers to investigate its effects on brain activation during emotional processing. The drug is still in clinical development and has not been approved by regulatory authorities.
GSK561679 targets the corticotropin-releasing factor receptor, which is involved in the body's stress response. By modulating this receptor, the drug may influence emotional processing and potentially affect symptoms of depression and anxiety. This mechanism was studied in a Phase 1 trial measuring brain activation during emotional tasks.
GSK561679 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company conducted a Phase 1 clinical trial of the drug in the United States to evaluate its effects on brain activity in healthy female volunteers.
GSK561679 is in Phase 1 clinical development. A Phase 1 trial with the identifier NCT00513565 was completed, involving 22 healthy female volunteers in the United States. The drug is investigational and has not received FDA approval for any indication.
GSK561679 was studied in one completed Phase 1 clinical trial, NCT00513565, titled "A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers." The trial enrolled 22 healthy female participants aged 18 years and older in the United States.
GSK561679 is a distinct investigational compound and is not known to be the same as any other marketed drug. It is being developed specifically for potential use in depressive and anxiety disorders, and its development is separate from other GSK products.